Literature DB >> 15623449

Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.

Angelita Habr-Gama1, Rodrigo Oliva Perez, Wladimir Nadalin, Sérgio Carlos Nahas, Ulysses Ribeiro, Afonso Henrique Silva E Sousa, Fábio Guilherme Campos, Desidério Roberto Kiss, Joaquim Gama-Rodrigues.   

Abstract

Neoadjuvant chemoradiation treatment (CRT) has resulted in significant tumor downstaging and improved local disease control for distal rectal cancer. The purpose of the present study was to determine the correlation between final stage and survival in these patients regardless of initial disease stage. Two hundred sixty patients with distal (0-7 cm from anal verge) rectal adenocarcinoma considered resectable were treated by neoadjuvant CRT with 5-FU and leucovorin plus 5040 cGy. Patients with incomplete clinical response 8 weeks after CRT completion were treated by radical surgical resection. Patients with complete clinical response were managed by observation alone. Overall survival and disease-free survival were compared according to Kaplan-Meier curves and log-rank tests according to final stage. Seventy-one patients (28%) showed complete clinical response (clinical stage 0). One hundred sixty-nine patients showed incomplete clinical response and were treated with surgery. In 22 of these patients (9%), pathologic examination revealed pT0 N0 M0 (stage p0), 59 patients (22%) had stage I, 68 patients (26%) had stage II, and 40 patients (15%) had stage III disease. Overall survival rates were significantly higher in stage c0 (P=0.01) compared with stage p0. Disease-free survival rate showed better results in stage c0, but the results were not significant. Five-year overall and disease-free survival rates were 97.7% and 84% (stage 0); 94% and 74% (stage I); 83% and 50% (stage II); and 56% and 28% (stage III), respectively. Cancer-related overall and disease-free survival may be correlated to final pathologic staging following neoadjuvant CRT for distal rectal cancer. Also, stage 0 is significantly associated with improved outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15623449     DOI: 10.1016/j.gassur.2004.10.010

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  29 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

Review 2.  [Rectal cancer: treatment and results].

Authors:  P Luna Pérez
Journal:  Rev Invest Clin       Date:  2001 Jan-Feb       Impact factor: 1.451

3.  Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer.

Authors:  K Yamada; T Ishizawa; K Niwa; Y Chuman; S Akiba; T Aikou
Journal:  Br J Surg       Date:  2001-07       Impact factor: 6.939

4.  The impact of recurrent rectal cancer on quality of life.

Authors:  J Camilleri-Brennan; R J Steele
Journal:  Eur J Surg Oncol       Date:  2001-06       Impact factor: 4.424

Review 5.  Morbidity and mortality following abdominoperineal resection for low rectal adenocarcinoma.

Authors:  P Luna-Pérez; S Rodríguez-Ramírez; J Vega; E Sandoval; S Labastida
Journal:  Rev Invest Clin       Date:  2001 Sep-Oct       Impact factor: 1.451

6.  Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.

Authors:  N A Janjan; V S Khoo; J Abbruzzese; R Pazdur; R Dubrow; K R Cleary; P K Allen; P M Lynch; G Glober; R Wolff; T A Rich; J Skibber
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

7.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

8.  Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.

Authors:  B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner
Journal:  J Natl Cancer Inst       Date:  1988-03-02       Impact factor: 13.506

9.  Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma.

Authors:  Isabelle Bedrosian; Miguel A Rodriguez-Bigas; Barry Feig; Kelly K Hunt; Lee Ellis; Steven A Curley; Jean Nicolas Vauthey; Marc Delclos; Christopher Crane; Nora Janjan; John M Skibber
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

10.  Optimal preoperative assessment and surgery for rectal cancer may greatly limit the need for radiotherapy.

Authors:  M Simunovic; R Sexton; E Rempel; B J Moran; R J Heald
Journal:  Br J Surg       Date:  2003-08       Impact factor: 6.939

View more
  46 in total

1.  Diffusion-weighted magnetic resonance imaging for predicting the response of rectal cancer to neoadjuvant concurrent chemoradiation.

Authors:  Gang Cai; Ye Xu; Ji Zhu; Wei-Lie Gu; Shuai Zhang; Xue-Jun Ma; San-Jun Cai; Zhen Zhang
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Fábio G Campos; Wladimir Nadalin; Desiderio Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

3.  Re: Salvaging a linear staple line defect in ultra-low anterior resection.

Authors:  Y-H Ho
Journal:  Tech Coloproctol       Date:  2008-03       Impact factor: 3.781

Review 4.  How does genome sequencing impact surgery?

Authors:  Marlies S Reimers; Charla C Engels; Peter J K Kuppen; Cornelis J H van de Velde; Gerrit J Liefers
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

Review 5.  Predicting complete response: is there a role for non-operative management of rectal cancer?

Authors:  T Jonathan Yang; Karyn A Goodman
Journal:  J Gastrointest Oncol       Date:  2015-04

6.  Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report.

Authors:  Khaled M Madbouly; Ahmed M Hussein
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

7.  The impact of surgical diversion before neoadjuvant therapy for rectal cancer.

Authors:  Brandon J Anderson; Elizabeth G Hill; Robert E Sweeney; Amy E Wahlquist; David T Marshall; Kevin F Staveley O'Carroll; David J Cole; Ernest Ramsay Camp
Journal:  Am Surg       Date:  2015-05       Impact factor: 0.688

8.  Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy.

Authors:  Anna Margherita Maffione; Alice Ferretti; Gaia Grassetto; Elena Bellan; Carlo Capirci; Sotirios Chondrogiannis; Marcello Gava; Maria Cristina Marzola; Lucia Rampin; Claudia Bondesan; Patrick M Colletti; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-16       Impact factor: 9.236

Review 9.  Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.

Authors:  Valerie M Nelson; Al B Benson
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

10.  miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy.

Authors:  Elrasheid A H Kheirelseid; Nicola Miller; Kah Hoong Chang; Catherine Curran; Emer Hennessey; Margaret Sheehan; John Newell; Christophe Lemetre; Graham Balls; Michael J Kerin
Journal:  Int J Colorectal Dis       Date:  2012-08-18       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.